At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
BIIB111drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia With Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
In Brief
A Phase 2 clinical trial evaluating BIIB111 for Choroideremia. Completed, enrolled 66 participants across 6 sites in 3 countries.
Detailed Summary
The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroideremia
CountriesFrance, Germany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedApr 2018
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 25, 2018
Enrollment StartNov 29, 2017
Primary CompletionJun 29, 2022
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.2 years ago
Interventions
BIIB111drug
Administered as specified in the treatment arm.